홈MCP워크벤치Skills
홈워크벤치알림마이페이지
llms.txt · MCP 가이드개인정보처리방침 · 이용약관 · 지원v1.8.0
  1. 홈
  2. /화합물

Pamidronic Acid

HCID 4674
새 노트새 반응견적 요청하기
인쇄 미리보기

데이터를 보충하는 중입니다. 잠시 후 페이지를 새로 고치면 최신 내용을 볼 수 있습니다

기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
부분 구조 검색유사 구조 찾기

기본 정보

CAS
40391-99-9
표준 SMILES
NCCC(O)(P(=O)(O)O)P(=O)(O)O
InChIKey
WRUUGTRCQOWXEG-UHFFFAOYSA-N
분자식
C3H11NO7P2
평균 분자량
235.07 g/mol
단동위원소 질량
235.00107495

개요

Pamidronate is a phosphonoacetic acid.

이름 및 식별자

우선 이름
Pamidronic Acid
IUPAC
(3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acid
영어명
Pamidronic acid
분자식
C3H11NO7P2
분자량
235.07

이름 및 동의어

PAMIDRONIC ACIDpamidronate40391-99-9AmidronateAcide pamidronique(3-amino-1-hydroxy-1-phosphonopropyl)phosphonic acidAcido pamidronicoAcidum pamidronicumRibodroat(3-Amino-1-hydroxypropylidene)bisphosphonic acidDTXSID4023414AHPrBP
이름 더 보기
(3-Amino-1-hydroxypropane-1,1-diyl)bis(phosphonic acid)DLVPanolinRescriptorPamidronicaciIflab-bb F1977-0047Delavirdine mesylate
OYY3447OMC(3-Amino-1-hydroxypropylidene)diphosphonic acidDTXCID003414(3-amino-1-hydroxypropylidene)-1,1-biphosphonateaminopropanehydroxydiphosphonateamino-1-hydroxypropane-1,1-diphosphonateRefChem:57113M05BA03

데이터베이스 식별자

CAS
40391-99-9
PubChem CID
4674
DTXSID
DTXSID4023414
ChEMBL
CHEMBL834
ChEBI
CHEBI:7903
UNII
OYY3447OMC
EC Number
254-905-2
Nikkaji
J221.669H

물성

구조 계산 물성보충 중

XLogP
-6.9
극성 표면적
161 Ų
수소 결합 공여자 수
6
수소 결합 수용자 수
8
회전 가능 결합 수
4
무거운 원자 수
13
형식 전하
0
복잡도
243

실험 및 물리화학적 성질

Drugs · 2건

Pharmaceuticals

Pharmaceuticals -> Listed in ZINC15

LogP-4.7
Solubility1.58e+01 g/L
Human DrugsBreast Feeding; Lactation; Milk, Human; Bisphosphonates; Bone Density Conservation Agents; Diphosphonates
Melting Point254-262
Physical DescriptionSolid

물리화학적 성질

녹는점
226 · 226-228°C
끓는 점
658.7 · 658.7±65.0 °C(Predicted)
밀도
1.998 · 1.998±0.06 g/cm3(Predicted)
저장 조건
2 · under inert gas (nitrogen or Argon) at 2–8 °C
용해도
메탄올(약간 용해됨, 가열, 초음파 처리), 물(약간 용해됨, 가열, 초음파 처리)
산도 계수 (pKa)
1.44 · 1.44±0.10(Predicted)
물리적 상태
고체
색상
라이트 브라운부터 베이지까지

안전 및 규제

안전 정보는 참고용이며, 공급업체의 물질안전보건자료(SDS), 관련 법규 및 전문가 평가를 대체하지 않습니다.

GHS 분류

GHS Classification · 4건

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]

P264, P270, P301+P317, P330, and P501 (click each P-code to see the statement)

Aggregated GHS information provided per 24 reports by companies from 4 notifications to the ECHA C&L Inventory.

유해성 정보

Hazard Classes and CategoriesAcute Tox. 4 (100%)

독성 정보

TreatmentIf overdosage occurs, symptomatic hypocalcemia could also result; such patients should be treated with short-term intravenous calcium. (L1712)
Health EffectsRare cases of uveitis, iritis, scleritis, and episcleritis have been reported, including one case of scleritis, and one case of uveitis upon separate rechallenges.
Adverse EffectsPamidronate correlates with numerous adverse effects, including hypocalcemia and resulting secondary hyperparathyroidism, acute phase response, musculoskeletal pain, various ocular events, and osteonecrosis of the jaw.
Exposure RoutesParenteral (intravenous). Plasma concentration rises rapidly upon IV administration.
Toxicity Summary · 2건

A small number of cases describe symptomatic hypocalcemia following pamidronate administration. In each case, however, patients had pre-existing derangements contributing to their symptoms, including renal insufficiency and low vitamin D levels secondary to lifestyle, previous GI surgery, and medication history. Recommendations for the management of pamidronate overdose include appropriate correction of the electrolyte disturbance and pre-treatment supplementation with calcium and Vitamin D.

화학 및 산업

약리 정보

ATC Code · 3건

M05BA03

M - Musculo-skeletal system

QM - Musculo-skeletal system

Protein BindingPamidronate is approximately 54% protein bound in serum.
Pharmacodynamics · 1건

Pamidronic acid is a second generation, nitrogen containing bisphosphonate that inhibits osteoclast mediated bone loss It has a wide therapeutic index and a long duration of action as it can be given every 3-4 weeks for certain indications. Patients should be counselled regarding the risk of elevated blood urea nitrogen, renal tubular necrosis, and nephrotoxicity.

Mechanism of Action · 1건

Bisphosphonates are taken into the bone where they bind to hydroxyapatite. Bone resorption by osteoclasts causes local acidification, releasing the bisphosphonate, which is taken into the osteoclast by fluid-phase endocytosis. Endocytic vesicles become acidified, releasing bisphosphonates into the cytosol of osteoclasts where they act. Osteoclasts mediate resorption of bone. When osteoclasts bind to bone they form podosomes, ring structures of F-actin. Disruption of the podosomes causes osteoclasts to detach from bones, preventing bone resorption. Nitrogen containing bisphosphonates such as pamidronate are known to induce apoptosis of hematopoietic tumor cells by inhibiting the components of the mevalonate pathway farnesyl diphosphate synthase, farnesyl diphosphate, and geranylgeranyl diphosphate. These components are essential for post-translational prenylation of GTP-binding proteins like Rap1. The lack of prenylation of these proteins interferes with their function, and in the case of Rap1, leads to apoptosis. pamidronate also activated caspases 3 and 9 which further contribute to apoptosis.

Biological Half-LifeThe mean elimination half life of pamidronate is 28±7 hours.
Metabolism/Metabolites · 2건

Pamidronate is not metabolized _in vivo_.

Pamidronate is not metabolized and is exclusively eliminated by renal excretion. Route of Elimination: Pamidronate is not metabolized and is exclusively eliminated by renal excretion. Half Life: The mean ± SD elimination half-life is 28 ± 7 hours

관련 반응

21건
반응 기록 만들기
HRID 49739 반응식
HRID 49739반응물로uspto-grants-2004_03
HRID 74141 반응식
HRID 74141반응물로uspto-grants-2014_09
HRID 412673 반응식
HRID 412673생성물로uspto-grants-2003_05
HRID 980773 반응식
HRID 980773반응물로uspto-grants-1987_01
HRID 980774 반응식
HRID 980774반응물로uspto-grants-1987_01
HRID 980775 반응식
HRID 980775반응물로uspto-grants-1987_01
HRID 980776 반응식
HRID 980776반응물로uspto-grants-1987_01
HRID 980777 반응식
HRID 980777반응물로uspto-grants-1987_01
1 / 3 페이지

화합물 노트

불러오는 중…

이 페이지에서기본 정보개요이름 및 식별자물성안전 및 규제화학 및 산업관련 반응화합물 노트
더보기
새 노트새 반응견적 요청하기
안정성
흡습성
InChI
InChI=1S/C3H11NO7P2/c4-2-1-3(5,12(6,7)8)13(9,10)11/h5H,1-2,4H2,(H2,6,7,8)(H2,9,10,11)
InChIKey
WRUUGTRCQOWXEG-UHFFFAOYSA-N
SMILES
C(P(=O)(O)O)(P(=O)(O)O)(O)CCN

화학적 성질

White Solid

The mechanism of action of pamidronate is inhibition of bone resorption. Pamidronate adsorbs to calcium phosphate (hydroxyapatite) crystals in bone and may directly block dissolution of this mineral component of bone. In vitro studies also suggest that inhibition of osteoclast activity contributes to inhibition of bone resorption. Pamidronate also targets farnesyl pyrophosphate (FPP) synthase. Nitrogen-containing bisphosphonates (such as pamidronate, alendronate, risedronate, ibandronate and zoledronate) appear to act as analogues of isoprenoid diphosphate lipids, thereby inhibiting FPP synthase, an enzyme in the mevalonate pathway. Inhibition of this enzyme in osteoclasts prevents the biosynthesis of isoprenoid lipids (FPP and GGPP) that are essential for the post-translational farnesylation and geranylgeranylation of small GTPase signalling proteins. This activity inhibits osteoclast activity and reduces bone resorption and turnover. In postmenopausal women, it reduces the elevated rate of bone turnover, leading to, on average, a net gain in bone mass.

Signs and SymptomsSide effects include an allergic reaction, kidney problems, seizures, low levels of calcium, magnesium, or phosphorus in the blood
Carcinogen ClassificationNo indication of carcinogenicity to humans (not listed by IARC).
Drug Induced Liver Injury · 5건

Drug-Induced Liver Injury Severity and Toxicity (DILIst)

pamidronate

DILI Negative

Intravenous

DOI:10.1016/j.drudis.2019.09.022

Effects During Pregnancy and Lactation◉ Summary of Use during Lactation

안전 데이터

HS 번호
9999999999
FDA Pharmacological Classification · 5건

OYY3447OMC

PAMIDRONIC ACID

Established Pharmacologic Class [EPC] - Bisphosphonate

Chemical Structure [CS] - Diphosphonates

Pamidronic acid is a Bisphosphonate.

MeSH Pharmacological ClassificationAgents that inhibit BONE RESORPTION and/or favor BONE MINERALIZATION and BONE REGENERATION. They are used to heal BONE FRACTURES and to treat METABOLIC BONE DISEASES such as OSTEOPOROSIS.
Absorption, Distribution and Excretion · 3건

In patients with a creatinine clearance >90mL/min, a 90mg intravenous dose reached a Cmax of 1.92±1.08µg/mL, with a Tmax of 4h, and an AUC of 10.2±6.95µg\*h/mL. In patients with a creatinine clearance 61-90mL/min, a 90mg intravenous dose reached a Cmax of 1.86±0.50µg/mL, with a Tmax of 4h, and an AUC of 10.7—3.91µg\*h/mL.[A203264 In patients with a creatinine clearance 30-60mL/min, a 90mg intravenous dose reached a Cmax of 1.84±0.58µg/mL, with a Tmax of 4h, and an AUC of 10.1±3.38µg\*h/mL. In patients with a creatinine clearance <30mL/min, a 90mg intravenous dose reached a Cmax of 1.93±0.53µg/mL, with a Tmax of 4h, and an AUC of 34.0±8.37µg\*h/mL.

Pamidronate is exclusively eliminated in the urine. By 120 hours after administration, 46±16% of the dose has been eliminated in the urine.

The mean total clearance of pamidronate is 107±50mL/min and the mean renal clearance is 49±28mL/min.

Cellular LocationsCytoplasm
Metabolite PathwaysPamidronate Action Pathway

용도 및 제조

Uses · 2건

Use (kg; approx.) in Germany (2009): >10

Pamidronate is in a class of drugs called bisphosphonates. Pamidronate reduces breakdown of the bones. Pamidronate is used in the treatment of Paget's disease of bone; to reduce high levels of calcium in the blood associated with malignancy (cancer); and to reduce the breakdown of bone due to metastases of breast cancer or multiple myeloma. For the treatment of moderate or severe hypercalcemia associated with malignancy

응용 분야

용도anticancer

상·하류 제품 정보

상류 원료

베타-알라닌삼염화 인Disodium pamidronateActivated carbon,decolor수산화나트륨마니톨